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Prognosis and Biomarkers: Raj Mookerjee 
From early descriptions of the syndrome some 13 years ago [Jalan and Williams Blood 
Purif 2002; 20(3):252-61] extra-hepatic organ failure and a systemic inflammatory 
response were considered important factors underpinning the evolution of ACLF and 
thereby entities to include in prognostic assessment. Scrolling forward a decade, and 
with a much clearer definition of the syndrome [Moreau et al, Gastro 2013; 144:1426-
37], it is now recognized that ACLF is a very dynamic syndrome where up to 50% of 
patients may undergo complete resolution from the decompensation event. With this 
comes the understanding that the short-term mortality is most accurately determined 
by the evolution of the clinical course from initial presentation to final ACLF grade 
obtained (usually within 7 days of presentation). [Gustot et al Hepatol 2015;62(1): 243-
52].  
Scoring systems for ACLF: 
Whilst conventional scoring systems such as the Child Pugh and Model for End-Stage 
Liver Disease (MELD) scores and their variants have been used to define prognosis 
in cirrhosis and determine the utility of transplantation, they are limited in their 
prognostic accuracy in ACLF due to a failure to incorporate two central prognostic 
determinants, namely, extra-hepatic organ failures and measures of systemic 
inflammation. These two entities underpin the pathophysiological basis of the 
syndrome of ACLF.  The recent large European multi-center prospective clinical study 
evaluating over 1300 hospitalized patients with cirrhosis complications- the CANONIC 
study- (Moreau R et al, Gastroenterology. 2013;144:1426-37), has helped define the 
phenotypes of ACLF patients. However, importantly, the study also helped assess the 
currently available prognostic scoring systems and enabled the development and 
validation of novel scoring systems for the prognosis of patients with ACLF (Jalan R 
et al, J Hepatol. 2014;61:1038-47) and acute decompensation (AD) (Jalan R et al, J 
Hepatol. 2015;62:831-40). Thus several grades of ACLF were classified using a 
modified sequential organ failure assessment (SOFA) score, evaluating liver, kidney, 
brain, coagulation, circulation and respiratory function (table 1). ACLF grades (1-3) 
were found to be highly predictive of mortality with significantly different outcomes. 
Response to treatment of ACLF patients may be monitored by daily calculation of the 
CLIF Consortium ACLF score (CLIF-C ACLFs), incorporating the CLIF-OF score, age 
and log-transformed white cell count (reflecting systemic inflammation). Ultimately, 
resolution of ACLF is the most important determinant of short and medium term 
mortality and the CLIF-C scores provide an objective measure of this. The CLIF-C 
ACLFs has since been independently validated with proven superior prognostic 
accuracy for ACLF compared to conventional scoring systems such as MELD, and 
Child-Pugh scores, and of note, provides a dynamic score to assess evolution to a 
potentially severe early course. It follows that such a scoring system facilitates a 
treatment algorithm whereby, patients with high CLIF-C ACLF scores may be 
considered for liver transplantation. If ineligible for transplantation, without a 
demonstrable treatment response in the score with standard of care therapy by days 
3-7, consideration should be given to placing ceilings of care management. The scores 
are freely available on the CLIF Consortium website and also as an app that is 
downloadable on any mobile platform (ACLF Calculator, Cyberliver, UK).   
What remains unclear is whether such scoring systems, which are at best about 75 
percent accurate, apply effectively to all etiologies of liver disease, with an increased 
appreciation of an ‘Asian’ viral hepatitis B predominant phenotype of ACLF where 
there is largely a hepatic hit, compared to a ‘Western’ alcohol and viral hepatitis C 
predominant ACLF, where extrahepatic disease is commonly described. The 
heterogeneity of existing definitions of ACLF between Asia-Pacific [Garg et al, Dig 
Liver Dis 2012; 44(2): 166-71] and Europe-North America [Olson and Kamath Curr 
Opin Crit Care 2011; 17(2):165-9] have added to the lack of clarity for the importance 
of precipitating factors, the key role of systemic inflammation and the liver-centric focus 
of the acute insult. Moreover, scoring systems applied to cirrhosis decompensation 
such as MELD are believed to have limitations in the context of an inflammatory 
syndrome such as ACLF, largely from the limitations of creatinine as a weighted 
parameter in this setting. In addition, many aetiology specific scoring systems exist, 
especially for alcoholic hepatitis, such as the Maddrey score, Lille score and Glasgow 
scores. However, how the CLIF-C score compares with these other scores requires 
assessment in prospective future studies. Thus unanswered questions remain as to 
(i) whether there are different pathophysiological processes that underlie the different 
etiologies and precipitant expressions of ACLF; (ii) In the absence of gold standard 
markers of prognosis to render one ‘scoring system’ superior to another, are other 
markers of pathophysiology more apt to define outcome?. It follows that a more 
detailed characterization of factors reflecting inflammation, nature of liver injury and 
markers of extra-hepatic organ function in these different settings, may be more 
effective as biomarkers of prognosis. This review aims to explore these factors in more 
detail.  
Markers of outcome in ACLF:  
The main rationale for pursuing a reliable biomarker in ACLF is to help with early 
detection of evolution of the syndrome in patients likely to evolve to a severe 
prognostic group. In such patients, timely intensive intervention may facilitate reversal 
of the process or/and improve survival, and define those patients who may benefit 
from fast-track listing for liver transplantation. Conversely, in patients defined as too 
advanced with futility as mortality approaches 75-100 percent, there is a health 
economic argument that costly interventions such as liver support should be avoided 
in place of end-of-life supportive care. As stated above, deploying the CLIF-Organ 
Failure score within the first week of evolution of decompensation, enables a dynamic 
score to help guide treatment allocation since this has been suggested to best stratify 
patients by their clinical and prognostic significance.[Jalan J Hep 2014; 61:1038-47] 
An observation worthy of note when deploying this score in a dynamic way is that 
precipitating events such as alcohol use and presence of infection do not appear to 
have a statistically significant bearing on 28-day or 90-day mortality.  
Oxidative Stress Factors: 
Inflammation and oxidative stress are believed to be key pathophysiological processes 
in the development of ACLF [Jalan Curr Opin Crit Care 2011;17(2): 152]. Indeed, 
studies have explored the role of inexpensive clinical markers such as CRP in the 
context of acute cirrhosis decompensation, and shown them to improve upon the 
prognostic utility of MELD score [Di Martino V et al, Liver Transpl 2015; 21(6) 753-60], 
highlighting the role of inflammation in this process. However, the application of 
different cut-off values for CRP across institutions limits interpretation of such data. 
Similarly, lack of resolution of inflammatory response is implied by the incorporation of 
white blood cell count into the CLIF-C ACLF score. However, these global systemic 
inflammatory markers still fail to indicate the degree of local hepatic and organ specific 
injury. To this end, small studies such as by Cai et al [Clin Res hepatol and 
Gastroenterol 2016; 40(1): 41-50] in patients with hepatitis B related ACLF reflect the 
impact of hepatic oxidative stress, denoted by advanced oxidation protein products, 
binding to their receptors such as RAGE, to trigger hepatocyte apoptosis and necrosis. 
Their data show that dynamic plasma levels of S100A12 and sRAGE could define the 
group of non-survivors. From the pathophysiological perspective, increased oxidation 
products are likely to drive activation of inflammatory cells such as neutrophils and 
monocytes, with the resulting cytokine cascade promoting further organ injury. This is 
reflected by increased generation of HMGB1 in non-survivors, which serves as a 
marker of pro-inflammatory drive. [Sha Y et al, J Immunol 2008; 180(4): 2531-7] 
Moreover, during inflammation, oxidation of albumin with the development of non-
mercaptalbumin 1 and 2 has been shown to directly impact on binding quality of 
albumin with prognostic implication for 30- and 90-day survival. [Oettl K et al, J Hepatol 
2013; 59(5): 978-83]. Oxidation of albumin also leads to the generation of ischaemia 
modified albumin, which may also serve as a prognostic index in ACLF [Jalan et al, 
Hepatology 2009; 50(2); 555-64] and provides some rationale for the benefits of 
albumin infusion therapy in ACLF.  
Markers of Cell Death: 
The impact of cell death as a consequence of hepatic inflammation has also been 
explored as potential biomarkers in ACLF. Cao and colleagues studied the caspase 
cleaved neo-epitope of cyto-keratin18 (M-30 antigen) indicating hepatocyte apoptotic 
death and the intact K-18 variants (M-65 antigen) reflecting total death of hepatocytes, 
in patients with hepatitis B ACLF.[Cao Z et al. Sci Rep 2015; 18(5):14240] The ratio of 
M30/M65 was used to indicate apoptosis rate, which at basal levels was considerably 
higher in patients with ACLF compared to chronic HBV cirrhosis. Of interest, they 
found that dynamic measurement of M30/M65 as a percentage of day 1 values of M30 
antigen, increased in survivors, suggesting an important role of apoptosis in the 
recovery of HBV-ACLF. Another study assessing M-30 and M-65 in plasma from a 
mixed UK population presenting with ACLF showed M-30 to be significantly elevated 
in non-survivors and in those patients with extra-hepatic failure. [Adebayo D et al, Liver 
Int 2015;35(12)2564-74] This questions whether such markers of apoptosis can also 
be used as targets for therapy. However, whilst excessive hepatocyte death is 
undoubtedly a key event in the development of ACLF, it raises new questions over the 
importance of which mode of cell death predominates as ACLF progresses. 
Hepatocyte regeneration may well necessitate activation of caspases [Ben Moshe T 
et al Hepatology 2007; 45(4):1014-24], but the exact balance of apoptosis versus 
necrosis as mode of cell death in ACLF clearly requires further study. Furthermore, as 
plasma measures of M30 antigen are made increasing available, it raises the 
possibility for an early prognostic biomarker in patients with ACLF which warrants 
further evaluation across different precipitants of ACLF. Cao et al did demonstrate that 
measures of cell death when added to traditional prognostic scores such as MELD-
Na, did provide superior prognostic utility. Again, the addition of such markers to 
scores such as the CLIF-C ACLF score requires further study.  
 
Immune dysfunction and Gut Dysbiosis: 
With advancing cirrhosis or/and an acute hepatic hit, there is significant loss of gut 
barrier integrity and increased bacterial translocation with pathogen associated 
molecular patterns (PAMPs) triggering immune activation. [Mencin A et al, Gut 2009; 
58(5):704-20] Current theory suggests that in ACLF, there is relative immune 
dysregulation with loss of functional adaptive and innate immune responses, resulting 
in an immune-paretic state and increased incidence of sepsis. [Gustot T et al, 
Hepatology 2015; 62(1): 243-52] Recent data suggests that in ACLF patients there 
are increased numbers of monocytes and macrophages expressing the receptor 
tyrosine kinase MERTK+, which in turn down regulates innate immune responses to 
microbial challenge. [Bernsmeier C et al, Gastro 2015; 148(3): 603-15] MERTK+ cell 
expression correlated with the severity of hepatic and extrahepatic disease and 
systemic inflammatory responses and reduced the response of cultured monocytes to 
lipopolysaccharide. This follows on from earlier literature suggesting that monocyte 
HLA-DR expression was pathologically down regulated in decompensated cirrhosis 
[Wasmuth HE J Hepatol 2005; 42(2): 195-201]. Thus immune phenotyping studies in 
cohorts of ACLF may lead to characterization of an immune ‘fingerprint’ that best 
defines a group with a high risk of sepsis and mortality, and in need of early 
intervention with novel therapies such as potential use of MERTK inhibitors.    
Neutrophil dysfunction with high oxidative burst function and reduced phagocytosis 
has also been characterized in decompensated cirrhosis and is most marked in those 
with organ failure and is associated with increased mortality. [Mookerjee Hepatology 
2007; 46(3): 831-40] It is believed that this in part contributes to further hepatic injury 
through the liberation of increased oxidant species and as a consequence, reduced 
cellular ATP reserves contribute to impaired ability to phagocytose pathogens and 
consequent immune dysfunction.  
Recently, Ariza and colleagues [J Hep 2016- ePub] have studied neutrophil 
gelatinase-associated lipocalin (NGAL) in patients with ACLF. They show that the 
LCN2 gene is markedly upregulated in ACLF livers, and its product, NGAL, is 
increased in the urine and plasma of these patients. Importantly, they show that the 
predictive utility of NGAL remains even after adjustment is made for urinary function, 
given that NGAL levels are influenced by glomerular filtration. They found that urinary 
NGAL improved significantly the accuracy of MELD in predicting outcome. Urinary 
NGAL was shown to correlate with markers of liver failure (Bilirubin and INR) and also 
with measures of systemic inflammation (Interleukin-6). They propose that given the 
high levels of LCN2 gene in ACLF, urinary NGAL could be a reliable biomarker of 
ACLF. Clearly, this requires validation across different precipitants of ACLF and it 
would be interesting to note whether Urinary NGAL adds further to the dynamic 
predictive utility of the CLIF-C ACLF score.  
A further interesting approach has been to consider phenotyping the gut microbiome 
in ACLF patients, to assess the level of gut dysbiosis. A study by Chen et al in a mixed 
ACLF cohort, though the predominant etiology was hepatitis B, showed a marked 
decrease in relative abundance of Bacteroidetes and conversely, an increase in 
Firmicutes. [Chen et al, J Gastroenterol Hepatol 2015; 30(9): 1429-37] At the family 
level of bacteria, the Ruminococcaceae and Lachnospiraceae were significantly 
decreased in ACLF, whilst Streptococcaceae, Pasteurellaceae and Enterococcaceae 
were significantly increased. Pasteurellaceae was also noted to be significantly 
elevated in non-survivors whilst low levels of Lachnospiraceae were found in patients 
that died. Furtehrmore, IL-6 levels were noted to be negatively correlated with 
Ruminococcaceae and Lachnospiraceae. A further important finding in this study was 
that whilst the gut microbiota reached a new equilibrium following onset of ACLF, the 
use of antibiotics in management of these patients had only a limited impact on the 
composition of the gut microbiota. The short-term stability of the gut microbiota after 
onset of ACLF does suggest that such characterization might also be of diagnostic 
and prognostic benefit but clearly larger studies across different liver disease 
etiologies are needed to understand whether such microbial patterns can be 
generalized to all ACLF cases, and validated for prognostic utility.  
Measures reflecting Organ Failure: 
Haemodynamic derangement: ACLF has been described as aggravating portal 
hypertension and indeed it is well established that in patients with for example 
alcoholic hepatitis precipitated ACLF, the inflammatory response significantly 
increases intrahepatic resistance Indeed, there is a good correlation between 
histological grade of inflammation in ACLF and severity of portal hypertension 
[Mookerjee J Hepatol 2011; 55(5): 1103-11] Recently, Garg and co-workers have 
shown that baseline HVPG is a predictor of mortality in patients with ACLF and that 
the high early rise in portal pressure, may predispose to increased risk of variceal 
bleeding. [Garg et al, J Gastroenterol Hepatol, 2013; 28(8): 1361-7] Moreover, as a 
reflection of aggravation of the systemic hyperdynamic response, the presence of 
hyponatremia in ACLF was found to have an independent effect on 90-day survival 
after adjusting for other potential confounders. Patients with hyponatremia and ACLF 
had a three-month transplant-free survival of only 35.8% compared to 58.7% in those 
with ACLF without hyponatremia (P <0.001).[Cardenas et al, Crit Care 2014; 18(6): 
700] 
Most recently, emerging data has focused on the glycopeptide, Copeptin, which is 
released from the neurohypophysis along with vasopressin (AVP). Solà and 
colleagues show Copeptin levels in patients with decompensated cirrhosis had a 
significant direct correlation with MELD score, AVP levels, endogenous 
vasoconstrictor activation and kidney function parameters. Copeptin levels were most 
elevated in non-survivors and in patients that developed decompensation.[Solà E et 
al, J Hepatol 2016 epub] It follows that neuro-hormonal markers such as Copeptin, 
renin and metabolites of norepinephrine might serve as indicators of systemic 
activation of such important regulatory pathways in the context of ACLF and may add 
additional prognostic utility to standard physiological measures such as mean arterial 
pressure and HVPG, when incorporated in prognostic scores. Clearly this requires 
further study and validation. Biomarkers of microvascular dysfunction have also been 
implicated in ACLF, associated with the severity of inflammatory response. Large von 
Willebrand Factor complexes have been described in patients with alcoholic hepatitis 
through deficiency of ADAMTS13 and thought in part to contribute to microcirculatory 
dysfunction and multi-organ failure.[Matsuyama et al, Alcohol Clin Exp Res 2007; 
31(1-Suppl) S27-35], and provide prognostic utility in the context of sepsis [Reuken P 
et al, Liver Int 2015; 35(1): 37-45].  
Along a similar vein, asymmetric dimethylarginine, a potent endothelial NOS regulator, 
has been shown to be significantly elevated in liver failure in the context of hepatic 
inflammation [Mookerjee Liver Transpl 2007; 13(3): 400-5] and importantly, has 
prognostic utility in patients with ACLF secondary to alcoholic hepatitis [Mookerjee 
Hepatol 2007]. A subsequent study focused on a product of both ADMA and its stereo-
isomer Symmetric Dimethylarginine (SDMA), which is believed to have impact on 
expression of nitric oxide synthase but also to be a sensitive indicator of renal function. 
In a study of 52 patients with acute decompensation of cirrhosis, the comibined 
dimethylarginines predicted development of ACLF and also 28-day mortality. The 
addition of ischaemia modified albumin ratio (IMAR) to the dimethylarginine score 
enabled superior predictive utility for mortality with an area under receiver operator 
curve of 0.9 (CI: 0.82-0.99; sensitivity 92% and specificity 80%) Figure 1  [Mookerjee 
et al, Hepatology  853, vol 46 (4) Suppl 1, 2007, 615A]  An on-going study which has been 
evaluating the role of this marker in decompensated cirrhosis and ACLF is soon to be 
reported. 
Renal Failure: Given the findings of the CANNONIC study and the important 
prognostic role that development of renal failure plays in defining the first stage of 
ACLF [Moreau Gastro 2013; 144(7): 1426-37], an accurate marker of renal functional 
reserve is clearly required. As stated above, creatinine has significant short comings 
as a renal function marker in advanced cirrhosis and is perhaps in part the reason for 
why MELD has less apparent utility in ACLF compared to organ failure scores. Wan 
and colleagues assessed serum cystatin C in patients with HBV induced ACLF and 
were able to show that it predicted onset of acute kidney injury in ACLF, even when 
patients demonstrated normal serum creatinine range levels.[Wan et al, World J 
Gastroenterol 2013;19(48): 9432-8]. More recently, Ariza et al analyzed a panel of 
urinary biomarkers and showed that NGAL, in addition to osteopontin and trefoil-
factor-3 served as good markers for the development of ACLF and outcome. [Ariza X 
et al, PLoS One 2015; 10(6): e0128145]  Clearly, such findings require further 
validation in larger studies and in different etiologies but challenge the more standard 
criteria used in scores such as MELD.  
In summary, a number of markers of oxidative and cellular injury are emerging, along 
with factors that reflect organ specific injury. Whilst some such as urinary NGAL have 
been tested in large patient groups, most of these ‘biomarkers’ still require extensive 
validation in relevant, heterogenous populations of ACLF. Future studies, beyond just 
validation of the individual biomarkers, will focus on developing a composite marker, 
to be used in conjunction with clinical scoring systems that best predict response to 
early intervention in ACLF (first week of admission) and demonstrate the best 
prognostic utility. Further development will require refinement of biological assays that 
will allow point-of-care testing ideally in remote care settings, such that home 
monitoring of cirrhosis can become not just an aspiration but a reality to better serve 
this patient population.  
 
Figure 1:  
This 3-dimensional representation of the components of the DASIMAR score, namely, 
ADMA, SDMA and IMAR are shown for patients with compensated alcoholic cirrhosis 
(green); decompensated alcoholic cirrhosis who survive after recovering from their 
acute decompensation (blue); and those with ACLF as a consequence of alcoholic 
hepatitis (red). It is evident form the figure that those patients with acute 
decompensation, have higher ADMA and SDMA values, then the compensated 
cirrhosis group. However, the highest values for ADMA, SDMA and especially IMAR, 
are amongst the non-surviving group of alcoholic hepatitis patients following their 
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